2026 年3月以来，医药生物板块捷报频传，复星医药、科伦药业、君实生物、恒瑞医药等多家龙头及创新药企密集披露临床进展公告，覆盖新药临床试验获批、上市申请受理等关键节点。从具体动态来看，龙头药企持续夯实研发壁垒。复星医药（600196）于3月10日连发公告，披露控股子公司药品临床试验获批消息，叠加前期控股子公司提供担保的进展公告，研发与资本运作双轮驱动态势明确；科伦药业（002422）同日公告，...
Source Link2026 年3月以来，医药生物板块捷报频传，复星医药、科伦药业、君实生物、恒瑞医药等多家龙头及创新药企密集披露临床进展公告，覆盖新药临床试验获批、上市申请受理等关键节点。从具体动态来看，龙头药企持续夯实研发壁垒。复星医药（600196）于3月10日连发公告，披露控股子公司药品临床试验获批消息，叠加前期控股子公司提供担保的进展公告，研发与资本运作双轮驱动态势明确；科伦药业（002422）同日公告，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.